Evaluation of a selective screening for colorectal carcinoma: The Taiwan Multicenter Cancer Screening (TAMCAS) project

Tony Hsiu Hsi Chen, Ming Fang Yen, Mei Shu Lai, Shin Lan Koong, Cheng Yi Wang, Jau Min Wong, Teresa C. Prevost, Stephen W. Duffy

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

BACKGROUND. Although the efficacy of mass screening for colorectal carcinoma (CRC) with a fecal occult blood test has been demonstrated in several randomized trials, a mass screening approach used in countries with intermediate or low incidence of CRC might be costly. Screening high risk people may be an alternative approach, to aid in the prevention of death from CRC. However, the efficacy of CRC screening for high risk people in such countries is uncertain. METHODS. For this study, a multicenter design was devised to identify high risk groups without clinical symptoms related to CRC; these subjects were identified through the study of index cases of CRC in Taiwan. Colonoscopy, in combination with a fecal occult blood test or double-contrast barium enema, was used to screen high risk groups. A total of 8909 subjects were invited to attend screening. Of 8909, 81 with asymptomatic CRC were detected in one-shot screening. Markov models, in conjunction with a simulated approach, were proposed to estimate relevant parameters in relation to disease progression and to assess the effect of the interval between screenings on the efficacy of CRC screening for these high risk groups. RESULTS. The estimated preclinical incidence rate was 0.00396 (95% confidence interval [CI], 0.002944-0.004985), which was 21 times that reported from a cancer registry in 1994. The simultaneous estimations of mean sojourn time (the average duration between the preclinical screen-detectable phase and the clinical phase) and sensitivity were 2.8 years (95% CI, 2.15-4.30) and 95.0% (95% CI, 24.4-99.9%), respectively. Predictions of mortality reduction for people who received annual, biennial, and triennial screening regimes compared with controls were 26% (95% CI, 0-50%), 23% (95% CI, 0-48%), and 21% (95% CI, 0-47%), respectively. CONCLUSIONS. The efficacy of selective colorectal carcinoma screening has been demonstrated in this study. A high preclinical CRC incidence rate also suggests that such a screening strategy might be cost-effective for countries with intermediate or low incidence of CRC. Methods proposed in this study can be used to evaluate the efficacy of CRC screening in similar screening trials.

Original languageEnglish
Pages (from-to)1116-1128
Number of pages13
JournalCancer
Volume86
Issue number7
DOIs
Publication statusPublished - Oct 1 1999
Externally publishedYes

Fingerprint

Taiwan
Early Detection of Cancer
Colorectal Neoplasms
Confidence Intervals
Occult Blood
Mass Screening
Incidence
Hematologic Tests
Colonoscopy
Registries
Disease Progression
Costs and Cost Analysis

Keywords

  • Colorectal carcinoma screening
  • High risk people
  • Markov model
  • Selective multicenter screening

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Evaluation of a selective screening for colorectal carcinoma : The Taiwan Multicenter Cancer Screening (TAMCAS) project. / Chen, Tony Hsiu Hsi; Yen, Ming Fang; Lai, Mei Shu; Koong, Shin Lan; Wang, Cheng Yi; Wong, Jau Min; Prevost, Teresa C.; Duffy, Stephen W.

In: Cancer, Vol. 86, No. 7, 01.10.1999, p. 1116-1128.

Research output: Contribution to journalArticle

Chen, Tony Hsiu Hsi ; Yen, Ming Fang ; Lai, Mei Shu ; Koong, Shin Lan ; Wang, Cheng Yi ; Wong, Jau Min ; Prevost, Teresa C. ; Duffy, Stephen W. / Evaluation of a selective screening for colorectal carcinoma : The Taiwan Multicenter Cancer Screening (TAMCAS) project. In: Cancer. 1999 ; Vol. 86, No. 7. pp. 1116-1128.
@article{d01589a9d06f4ceea6e788b663c5cf64,
title = "Evaluation of a selective screening for colorectal carcinoma: The Taiwan Multicenter Cancer Screening (TAMCAS) project",
abstract = "BACKGROUND. Although the efficacy of mass screening for colorectal carcinoma (CRC) with a fecal occult blood test has been demonstrated in several randomized trials, a mass screening approach used in countries with intermediate or low incidence of CRC might be costly. Screening high risk people may be an alternative approach, to aid in the prevention of death from CRC. However, the efficacy of CRC screening for high risk people in such countries is uncertain. METHODS. For this study, a multicenter design was devised to identify high risk groups without clinical symptoms related to CRC; these subjects were identified through the study of index cases of CRC in Taiwan. Colonoscopy, in combination with a fecal occult blood test or double-contrast barium enema, was used to screen high risk groups. A total of 8909 subjects were invited to attend screening. Of 8909, 81 with asymptomatic CRC were detected in one-shot screening. Markov models, in conjunction with a simulated approach, were proposed to estimate relevant parameters in relation to disease progression and to assess the effect of the interval between screenings on the efficacy of CRC screening for these high risk groups. RESULTS. The estimated preclinical incidence rate was 0.00396 (95{\%} confidence interval [CI], 0.002944-0.004985), which was 21 times that reported from a cancer registry in 1994. The simultaneous estimations of mean sojourn time (the average duration between the preclinical screen-detectable phase and the clinical phase) and sensitivity were 2.8 years (95{\%} CI, 2.15-4.30) and 95.0{\%} (95{\%} CI, 24.4-99.9{\%}), respectively. Predictions of mortality reduction for people who received annual, biennial, and triennial screening regimes compared with controls were 26{\%} (95{\%} CI, 0-50{\%}), 23{\%} (95{\%} CI, 0-48{\%}), and 21{\%} (95{\%} CI, 0-47{\%}), respectively. CONCLUSIONS. The efficacy of selective colorectal carcinoma screening has been demonstrated in this study. A high preclinical CRC incidence rate also suggests that such a screening strategy might be cost-effective for countries with intermediate or low incidence of CRC. Methods proposed in this study can be used to evaluate the efficacy of CRC screening in similar screening trials.",
keywords = "Colorectal carcinoma screening, High risk people, Markov model, Selective multicenter screening",
author = "Chen, {Tony Hsiu Hsi} and Yen, {Ming Fang} and Lai, {Mei Shu} and Koong, {Shin Lan} and Wang, {Cheng Yi} and Wong, {Jau Min} and Prevost, {Teresa C.} and Duffy, {Stephen W.}",
year = "1999",
month = "10",
day = "1",
doi = "10.1002/(SICI)1097-0142(19991001)86:7<1116::AID-CNCR4>3.0.CO;2-D",
language = "English",
volume = "86",
pages = "1116--1128",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Evaluation of a selective screening for colorectal carcinoma

T2 - The Taiwan Multicenter Cancer Screening (TAMCAS) project

AU - Chen, Tony Hsiu Hsi

AU - Yen, Ming Fang

AU - Lai, Mei Shu

AU - Koong, Shin Lan

AU - Wang, Cheng Yi

AU - Wong, Jau Min

AU - Prevost, Teresa C.

AU - Duffy, Stephen W.

PY - 1999/10/1

Y1 - 1999/10/1

N2 - BACKGROUND. Although the efficacy of mass screening for colorectal carcinoma (CRC) with a fecal occult blood test has been demonstrated in several randomized trials, a mass screening approach used in countries with intermediate or low incidence of CRC might be costly. Screening high risk people may be an alternative approach, to aid in the prevention of death from CRC. However, the efficacy of CRC screening for high risk people in such countries is uncertain. METHODS. For this study, a multicenter design was devised to identify high risk groups without clinical symptoms related to CRC; these subjects were identified through the study of index cases of CRC in Taiwan. Colonoscopy, in combination with a fecal occult blood test or double-contrast barium enema, was used to screen high risk groups. A total of 8909 subjects were invited to attend screening. Of 8909, 81 with asymptomatic CRC were detected in one-shot screening. Markov models, in conjunction with a simulated approach, were proposed to estimate relevant parameters in relation to disease progression and to assess the effect of the interval between screenings on the efficacy of CRC screening for these high risk groups. RESULTS. The estimated preclinical incidence rate was 0.00396 (95% confidence interval [CI], 0.002944-0.004985), which was 21 times that reported from a cancer registry in 1994. The simultaneous estimations of mean sojourn time (the average duration between the preclinical screen-detectable phase and the clinical phase) and sensitivity were 2.8 years (95% CI, 2.15-4.30) and 95.0% (95% CI, 24.4-99.9%), respectively. Predictions of mortality reduction for people who received annual, biennial, and triennial screening regimes compared with controls were 26% (95% CI, 0-50%), 23% (95% CI, 0-48%), and 21% (95% CI, 0-47%), respectively. CONCLUSIONS. The efficacy of selective colorectal carcinoma screening has been demonstrated in this study. A high preclinical CRC incidence rate also suggests that such a screening strategy might be cost-effective for countries with intermediate or low incidence of CRC. Methods proposed in this study can be used to evaluate the efficacy of CRC screening in similar screening trials.

AB - BACKGROUND. Although the efficacy of mass screening for colorectal carcinoma (CRC) with a fecal occult blood test has been demonstrated in several randomized trials, a mass screening approach used in countries with intermediate or low incidence of CRC might be costly. Screening high risk people may be an alternative approach, to aid in the prevention of death from CRC. However, the efficacy of CRC screening for high risk people in such countries is uncertain. METHODS. For this study, a multicenter design was devised to identify high risk groups without clinical symptoms related to CRC; these subjects were identified through the study of index cases of CRC in Taiwan. Colonoscopy, in combination with a fecal occult blood test or double-contrast barium enema, was used to screen high risk groups. A total of 8909 subjects were invited to attend screening. Of 8909, 81 with asymptomatic CRC were detected in one-shot screening. Markov models, in conjunction with a simulated approach, were proposed to estimate relevant parameters in relation to disease progression and to assess the effect of the interval between screenings on the efficacy of CRC screening for these high risk groups. RESULTS. The estimated preclinical incidence rate was 0.00396 (95% confidence interval [CI], 0.002944-0.004985), which was 21 times that reported from a cancer registry in 1994. The simultaneous estimations of mean sojourn time (the average duration between the preclinical screen-detectable phase and the clinical phase) and sensitivity were 2.8 years (95% CI, 2.15-4.30) and 95.0% (95% CI, 24.4-99.9%), respectively. Predictions of mortality reduction for people who received annual, biennial, and triennial screening regimes compared with controls were 26% (95% CI, 0-50%), 23% (95% CI, 0-48%), and 21% (95% CI, 0-47%), respectively. CONCLUSIONS. The efficacy of selective colorectal carcinoma screening has been demonstrated in this study. A high preclinical CRC incidence rate also suggests that such a screening strategy might be cost-effective for countries with intermediate or low incidence of CRC. Methods proposed in this study can be used to evaluate the efficacy of CRC screening in similar screening trials.

KW - Colorectal carcinoma screening

KW - High risk people

KW - Markov model

KW - Selective multicenter screening

UR - http://www.scopus.com/inward/record.url?scp=0033214795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033214795&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19991001)86:7<1116::AID-CNCR4>3.0.CO;2-D

DO - 10.1002/(SICI)1097-0142(19991001)86:7<1116::AID-CNCR4>3.0.CO;2-D

M3 - Article

C2 - 10506694

AN - SCOPUS:0033214795

VL - 86

SP - 1116

EP - 1128

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -